One major challenge in nanomedicine is the selective delivery of nanoparticles to diseased
tissues. Nanoparticle delivery systems require targeting for specific delivery to pathogenic …

The rapid development of nanotechnology provides alternative approaches to overcome
several limitations of conventional anti-cancer therapy. Drug targeting using functionalized …

Hematological malignancy like lymphoma originates in lymph tissues and has a propensity
to spread across other organs. Managing such tumors is challenging as conventional …

The state-of-the art in water-soluble macromolecular therapeutics has been reviewed. First
the design principles for polymer-drug conjugates are discussed followed by two recent …

With the rapid increase in the use of nanotechnology and immunotherapy for cancer
management in the recent past, there are great implications for using nanotechnology in …

This review highlights a new paradigm in macromolecular nanomedicine–drug-free
macromolecular therapeutics (DFMT). The effectiveness of the new system is based on …

This review highlights a unique research area in polymer-based nanomedicine designs.
Drug-free macromolecular therapeutics induce apoptosis of malignant cells by the …

A hybrid biomimetic system comprising high-molecular-weight, linear copolymer of N-(2-
hydroxypropyl) methacrylamide (HPMA) grafted with multiple Fab′ fragments of anti-CD20 …

Despite advances in chemo and immunotherapeutic agents for B chronic lymphocytic
leukemia (B-CLL), the undesirable adverse side effects due to non-specific cellular uptake …

The use of rituximab, an anti-CD20 mAb, in combination with chemotherapy is the current
standard for the treatment of B-cell lymphomas. However, because of a significant number of …